Insights & Resources

Public-sector procurement scandals show how lax vendor controls endanger taxpayer dollars. Learn key red flags and practical steps to reduce risk.

Simplify grant compliance with our step-by-step guide. Stay informed and organized to avoid audit risks and maximize funding impact.

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

Explore how proposed Medicaid cuts could impact health care valuations, reimbursement models and financial stability across various provider segments.

Discover how outsourcing in pharmaceutical manufacturing enhances quality, ensures compliance and mitigates risks in a rapidly evolving industry.

Several updates to HB 8 will affect Texas community colleges and their state funding. Here’s the breakdown and how they will affect campuses.

Discover 10 surprising ways Texas’ rapid growth and advancements are reshaping industries, driving business innovation and creating new opportunities.

Learn how HMRC's guidelines impact transfer pricing for life sciences and other multinationals and how to mitigate risks and ensure compliance.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

KPMG has released their 2024 biopharma report detailing the challenges and opportunities for pharma companies moving forward into the new year.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.